Xilio Therapeutics, Inc. Overview
Pro stress-test →Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company leverages its proprietary masking technology to advance a pipeline of novel, masked I-O molecules designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment.
Strategic Profile
Pro stress-test →Key programs include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 antibody being studied in combination with atezolizumab, and efarindodekin alfa (XTX301), a tumor-activated IL-12 in Phase 1/2 trials. The company has approximately $137.5 million in cash as of December 31, 2025, with funding extending its anticipated cash runway into Q2 2027.
Competitive Landscape
Pro stress-test →Xilio competes in the immuno-oncology space against established checkpoint inhibitor providers (Bristol Myers Squibb, Merck, Roche) and emerging cytokine/bispecific platforms. The masking technology represents a differentiation strategy to reduce systemic toxicity. Key competitive advantage lies in potentially achieving better therapeutic index through tumor-localized activation.
Industry Context
Xilio Therapeutics, Inc. operates in Biotechnology / Immuno-Oncology.
Key facts
Founded: 2016 · Headquarters: Waltham, Massachusetts